Every 8-K that Caris Life Sciences, Inc. (CAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAI filings page.
Caris Life Sciences, Inc. (CAI) reports that, beginning September 14, 2026, company representatives intend to use an investor presentation in meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference and at other investor events.
The investor presentation will be posted on the company’s investor relations website. The disclosure is furnished under Regulation FD and is expressly stated not to be “filed” or incorporated by reference for purposes of the Securities Exchange Act of 1934 or the Securities Act of 1933, except where specifically included in a future filing.
Caris Life Sciences, Inc. reported second quarter 2026 results and raised full-year 2026 revenue guidance to $1.03–$1.04 billion, representing growth of 27%–28% versus 2025.
For the quarter ended June 30, 2026, total revenue was $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services and approximately 59,200 clinical cases. Gross margin reached 68%, about 500 basis points higher than a year earlier. Net loss was $0.6 million, compared to $71.8 million in the prior-year quarter, and Adjusted EBITDA was $55.7 million.
Operating cash flow was $28.5 million and free cash flow $6.4 million. Cash, cash equivalents and restricted cash totaled 692,745 (amounts in thousands of dollars) at June 30, 2026. The company highlighted launches including Caris Detect and Caris ChromoSeq and a share repurchase program of up to $100 million, with approximately $82.1 million remaining authorized.
Caris Life Sciences, Inc. reported results of its 2026 Annual Meeting of Shareholders held on June 4, 2026. Shareholders elected ten directors to serve until the 2027 annual meeting and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
As of the April 9, 2026 record date, 282,662,545 common shares were issued, outstanding and eligible to vote, and 273,714,520 shares were represented at the meeting, constituting a quorum. Each director nominee received more votes for than withheld, and the auditor ratification proposal received substantially more votes for than against or abstaining.
Caris Life Sciences reported a strong first quarter of 2026 as revenue and profitability metrics improved sharply. Total revenue reached $216.2 million, up 79% from the prior-year quarter, driven by $210.8 million in molecular profiling services revenue, which grew 85%. The company completed about 52,800 clinical therapy selection cases, a 15% increase, and delivered a gross margin of 65%, up from 47%.
Operating income was positive and net loss narrowed to just $0.5 million, with Adjusted EBITDA of $26.2 million. Cash generation improved markedly: operating cash flow was $32.9 million and free cash flow was $22.5 million, even after $30.5 million in annual bonus payments. Management reaffirmed 2026 revenue guidance of $1.0–$1.02 billion, implying 23%–26% growth over 2025, and about 20% clinical therapy selection volume growth.
Caris Life Sciences, Inc. entered into a new senior secured credit agreement on April 1, 2026, providing an initial term loan of $400,000,000, a committed delayed draw term facility of up to $300,000,000, and an uncommitted incremental facility of up to $500,000,000.
The initial term loan funded at closing and matures in April 2031, while the delayed draw facility is available through August 2027 and may be used only for Permitted Acquisitions. Loans bear interest at a Term SOFR or Base Rate option plus margins of 5.00% or 4.00%, respectively, for the term and delayed draw loans.
The facilities are guaranteed by certain subsidiaries and secured by substantially all tangible and intangible personal property. The agreement includes customary covenants and events of default, and requires minimum qualified cash of $50 million at each fiscal quarter-end. The company used proceeds from the initial term loan to fully repay and terminate its January 18, 2023 credit agreement, including related guarantees and liens.
Caris Life Sciences delivered a breakout 2025, nearly doubling revenue and turning profitable in the fourth quarter. Q4 2025 revenue reached $292.9 million, up 125% year over year, with gross margin expanding to 75% and net income of $82.0 million. Full-year 2025 revenue was $812.0 million, up 97%, with gross margin improving to 66%. The company still reported a full-year net loss of $68.1 million, but generated positive Adjusted EBITDA of $137.7 million, operating cash flow of $83.2 million, and free cash flow of $66.9 million.
Management expects 2026 revenue of $1.0 billion to $1.02 billion, implying approximately 23% to 26% growth, driven by about 20% higher clinical therapy selection volume and 21% to 22% molecular profiling growth. They also expect to remain positive on free cash flow and Adjusted EBITDA. The company highlighted an interim readout from its Achieve 1 study supporting the planned first-half 2026 launch of Caris Detect, a multi-cancer early detection test, and recent partnerships with Everlywell and Genentech.
Caris Life Sciences, Inc. furnished an 8-K to report that it issued a press release with certain preliminary unaudited financial results for the quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference for this results disclosure. The company also states that materials used for its presentation at the 2026 J.P. Morgan Healthcare Conference will be posted to its investor relations website. The information in this report, including the exhibit, is being furnished rather than filed, which limits its use in other securities law contexts.
Caris Life Sciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025.
The release, dated November 5, 2025, is provided as Exhibit 99.1 and is incorporated by reference solely for Item 2.02. The company states this information is furnished, not filed, under the Exchange Act.
Caris Life Sciences (CAI) amended and restated its bylaws. Effective upon Board approval on October 30, 2025, a shareholder—defined under the Texas Business Organizations Code to include a group acting together—must beneficially own at least 3% of the company’s outstanding common stock at the time a case is filed to institute or maintain a derivative proceeding.
The change is described under Item 5.03 and incorporated into Item 3.03 as a material modification to rights of security holders. The full text of the amended and restated bylaws is provided as Exhibit 3.1.
Caris Life Sciences, Inc. filed a Form 8-K dated August 12, 2025 stating that the company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company expressly states the press release is furnished, not "filed," and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings except as expressly noted.
The report is signed by Luke Power, Senior Vice President, Chief Financial Officer and Chief Accounting Officer. The filing identifies the company’s common stock as trading under the symbol CAI on The Nasdaq Stock Market and indicates the registrant is an emerging growth company. For the actual financial figures, readers must consult the furnished press release in Exhibit 99.1.